Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BK4X
|
||||
| Former ID |
DAP001545
|
||||
| Drug Name |
Cinryze
|
||||
| Indication | Hereditary angioedema [ICD9: 277.6; ICD10:D84.1] | Approved | [1] | ||
| Target and Pathway | |||||
| Target(s) | C1 esterase inhibitor | Target Info | Modulator | [2] | |
| C1 esterase | Target Info | Modulator | [2] | ||
| KEGG Pathway | Complement and coagulation cascades | ||||
| Pertussis | |||||
| Staphylococcus aureus infection | |||||
| Systemic lupus erythematosus | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Complement Activation, Classical Pathway | |||||
| Human Complement System | |||||
| Complement cascade | |||||
| References | |||||
| REF 1 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | ||||
| REF 2 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.